| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | aspartic-type endopeptidase activity | 5.96e-09 | 37 | 36 | 5 | GO:0004190 | |
| GeneOntologyMolecularFunction | aspartic-type peptidase activity | 6.86e-09 | 38 | 36 | 5 | GO:0070001 | |
| GeneOntologyMolecularFunction | structural molecule activity | 1.51e-04 | 891 | 36 | 8 | GO:0005198 | |
| GeneOntologyMolecularFunction | actin binding | 1.95e-04 | 479 | 36 | 6 | GO:0003779 | |
| GeneOntologyMolecularFunction | phospholipid binding | 4.02e-04 | 548 | 36 | 6 | GO:0005543 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | 6.24e-04 | 1099 | 36 | 8 | GO:0008092 | |
| GeneOntologyMolecularFunction | actin filament binding | 7.20e-04 | 227 | 36 | 4 | GO:0051015 | |
| GeneOntologyMolecularFunction | zinc ion binding | 9.23e-04 | 891 | 36 | 7 | GO:0008270 | |
| GeneOntologyMolecularFunction | endopeptidase activity | 9.84e-04 | 430 | 36 | 5 | GO:0004175 | |
| GeneOntologyMolecularFunction | actin monomer binding | 1.24e-03 | 29 | 36 | 2 | GO:0003785 | |
| GeneOntologyMolecularFunction | structural constituent of muscle | 2.72e-03 | 43 | 36 | 2 | GO:0008307 | |
| GeneOntologyMolecularFunction | transition metal ion binding | 4.75e-03 | 1189 | 36 | 7 | GO:0046914 | |
| GeneOntologyBiologicalProcess | cardiac muscle thin filament assembly | 8.88e-06 | 3 | 36 | 2 | GO:0071691 | |
| GeneOntologyBiologicalProcess | 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate metabolic process | 1.77e-05 | 4 | 36 | 2 | GO:1902633 | |
| GeneOntologyBiologicalProcess | plasma membrane organization | 1.79e-05 | 188 | 36 | 5 | GO:0007009 | |
| GeneOntologyBiologicalProcess | viral process | 1.38e-04 | 464 | 36 | 6 | GO:0016032 | |
| GeneOntologyBiologicalProcess | membrane organization | 1.44e-04 | 914 | 36 | 8 | GO:0061024 | |
| GeneOntologyBiologicalProcess | actin filament organization | 2.28e-04 | 509 | 36 | 6 | GO:0007015 | |
| MousePheno | abnormal sarcomere morphology | 6.96e-06 | 77 | 23 | 4 | MP:0004090 | |
| MousePheno | abnormal Z line morphology | 3.69e-05 | 40 | 23 | 3 | MP:0004091 | |
| MousePheno | abnormal I band morphology | 4.28e-05 | 42 | 23 | 3 | MP:0030567 | |
| MousePheno | abnormal A band morphology | 1.16e-04 | 10 | 23 | 2 | MP:0030566 | |
| Domain | MIM/ABBA | 2.67e-06 | 2 | 31 | 2 | IPR030127 | |
| Domain | SH3_9 | 8.13e-06 | 78 | 31 | 4 | PF14604 | |
| Domain | NEBU | 1.60e-05 | 4 | 31 | 2 | SM00227 | |
| Domain | NEBULIN | 1.60e-05 | 4 | 31 | 2 | PS51216 | |
| Domain | Nebulin | 1.60e-05 | 4 | 31 | 2 | PF00880 | |
| Domain | Nebulin_repeat | 1.60e-05 | 4 | 31 | 2 | IPR000900 | |
| Domain | Nebulin | 1.60e-05 | 4 | 31 | 2 | IPR013998 | |
| Domain | IMD | 2.66e-05 | 5 | 31 | 2 | PS51338 | |
| Domain | IMD | 3.98e-05 | 6 | 31 | 2 | PF08397 | |
| Domain | SH3_1 | 1.50e-04 | 164 | 31 | 4 | PF00018 | |
| Domain | I-BAR_dom | 2.06e-04 | 13 | 31 | 2 | IPR013606 | |
| Domain | SH3 | 4.28e-04 | 216 | 31 | 4 | PS50002 | |
| Domain | SH3 | 4.28e-04 | 216 | 31 | 4 | SM00326 | |
| Domain | SH3_domain | 4.59e-04 | 220 | 31 | 4 | IPR001452 | |
| Domain | WH2 | 7.19e-04 | 24 | 31 | 2 | PS51082 | |
| Domain | Retrov_capsid_C | 4.30e-03 | 59 | 31 | 2 | IPR008916 | |
| Pubmed | A revised nomenclature for transcribed human endogenous retroviral loci. | 6.05e-10 | 94 | 36 | 6 | 21542922 | |
| Pubmed | 2.93e-09 | 18 | 36 | 4 | 18664271 | ||
| Pubmed | Quantitation of HERV-K env gene expression and splicing in human breast cancer. | 1.02e-08 | 5 | 36 | 3 | 12629516 | |
| Pubmed | 1.04e-06 | 2 | 36 | 2 | 19851499 | ||
| Pubmed | Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans. | 6.24e-06 | 4 | 36 | 2 | 10469592 | |
| Pubmed | 6.24e-06 | 4 | 36 | 2 | 23985323 | ||
| Pubmed | 6.24e-06 | 4 | 36 | 2 | 14752106 | ||
| Pubmed | ABBA regulates plasma-membrane and actin dynamics to promote radial glia extension. | 6.24e-06 | 4 | 36 | 2 | 18413296 | |
| Pubmed | Transcriptionally active HERV-K genes: identification, isolation, and chromosomal mapping. | 1.04e-05 | 5 | 36 | 2 | 11401426 | |
| Pubmed | Multiple Src Homology 3 Binding to the Ubiquitin Ligase Itch Conserved Proline-Rich Region. | 1.56e-05 | 6 | 36 | 2 | 26613292 | |
| Pubmed | 1.56e-05 | 6 | 36 | 2 | 28235806 | ||
| Pubmed | The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. | 2.18e-05 | 7 | 36 | 2 | 15856011 | |
| Pubmed | 2.91e-05 | 8 | 36 | 2 | 11309420 | ||
| Pubmed | The ABBA motif binds APC/C activators and is shared by APC/C substrates and regulators. | 4.66e-05 | 10 | 36 | 2 | 25669885 | |
| Pubmed | 6.83e-05 | 12 | 36 | 2 | 14557543 | ||
| Pubmed | 8.07e-05 | 13 | 36 | 2 | 21406566 | ||
| Pubmed | 9.41e-05 | 14 | 36 | 2 | 20854876 | ||
| Pubmed | 1.24e-04 | 16 | 36 | 2 | 25987543 | ||
| Pubmed | Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing. | 1.94e-04 | 523 | 36 | 5 | 11256614 | |
| Pubmed | Mapping the Ku Interactome Using Proximity-Dependent Biotin Identification in Human Cells. | 2.06e-04 | 283 | 36 | 4 | 30585729 | |
| Pubmed | The in vivo Interaction Landscape of Histones H3.1 and H3.3. | 3.87e-04 | 608 | 36 | 5 | 36089195 | |
| Pubmed | HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. | 4.86e-04 | 148 | 36 | 3 | 32538781 | |
| Pubmed | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. | 5.07e-04 | 32 | 36 | 2 | 23535730 | |
| Pubmed | 6.02e-04 | 1442 | 36 | 7 | 35575683 | ||
| Pubmed | 6.07e-04 | 35 | 36 | 2 | 24515614 | ||
| Pubmed | Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. | 8.33e-04 | 41 | 36 | 2 | 18157088 | |
| Pubmed | Characterization of the DOT1L network: implications of diverse roles for DOT1L. | 8.33e-04 | 41 | 36 | 2 | 20431927 | |
| Pubmed | 9.20e-04 | 1116 | 36 | 6 | 31753913 | ||
| Pubmed | 9.97e-04 | 750 | 36 | 5 | 11230166 | ||
| Pubmed | 1.00e-03 | 45 | 36 | 2 | 33596420 | ||
| Pubmed | Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. | 1.01e-03 | 432 | 36 | 4 | 23455922 | |
| Interaction | AFF1 interactions | 3.09e-06 | 66 | 31 | 4 | int:AFF1 | |
| Cytoband | 10p12 | 1.25e-05 | 7 | 36 | 2 | 10p12 | |
| Cytoband | 2q14 | 3.27e-05 | 11 | 36 | 2 | 2q14 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr10p12 | 1.84e-04 | 140 | 36 | 3 | chr10p12 | |
| Cytoband | 16q22.1 | 3.40e-03 | 110 | 36 | 2 | 16q22.1 | |
| GeneFamily | I-BAR domain containing | 6.42e-06 | 5 | 15 | 2 | 1287 | |
| Coexpression | LAKE_ADULT_KIDNEY_C22_ENDOTHELIAL_CELLS_GLOMERULAR_CAPILLARIES | 1.76e-05 | 137 | 30 | 4 | M39241 | |
| Coexpression | GSE40274_FOXP3_VS_FOXP3_AND_HELIOS_TRANSDUCED_ACTIVATED_CD4_TCELL_DN | 2.08e-05 | 143 | 30 | 4 | M9149 | |
| Coexpression | EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION | 2.26e-05 | 48 | 30 | 3 | M16123 | |
| Coexpression | GSE41867_NAIVE_VS_DAY15_LCMV_ARMSTRONG_EFFECTOR_CD8_TCELL_DN | 7.57e-05 | 199 | 30 | 4 | M9501 | |
| Coexpression | GSE557_WT_VS_CIITA_KO_DC_DN | 7.72e-05 | 200 | 30 | 4 | M6008 | |
| ToppCell | 3'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.23e-06 | 163 | 30 | 4 | e6213900f56257fe38ac7852351bea0340294be0 | |
| ToppCell | 3'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.23e-06 | 163 | 30 | 4 | ed7319185c1ec384444309bb8be95691a0c2091c | |
| ToppCell | 3'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.0.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.23e-06 | 163 | 30 | 4 | ef35d7ff09aa364734fea7fdaab6260c0a3fbf09 | |
| ToppCell | droplet-Spleen-nan-18m|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.54e-06 | 182 | 30 | 4 | eeb5dfa4539e9ca5220f26bc2b65717ddcf13b6c | |
| ToppCell | droplet-Spleen-nan-18m-Lymphocytic|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.68e-06 | 183 | 30 | 4 | 28cbf909424f3be4491d49832f0aca0386560814 | |
| ToppCell | droplet-Spleen-nan-18m-Lymphocytic-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.68e-06 | 183 | 30 | 4 | 3fa608aa6b119869ec3280dc388dfee57160e63a | |
| ToppCell | Sepsis-ICU-SEP-Lymphocyte-T/NK-NK_CD56bright|ICU-SEP / Disease, condition lineage and cell class | 8.94e-06 | 197 | 30 | 4 | c187e3fc2160b0165eb039cf09a6e621016068b7 | |
| ToppCell | COVID-19-COVID-19_Severe-Lymphocyte-T/NK-dn_T|COVID-19_Severe / Disease, condition lineage and cell class | 9.49e-06 | 200 | 30 | 4 | d01aa5fccada22f97d8350ad5888df2aadb5bb1c | |
| ToppCell | mild|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 9.49e-06 | 200 | 30 | 4 | 12f1685ce8f218433068e090c9d839cd5a1910bf | |
| ToppCell | Ionocyte-iono-4|World / Class top | 8.83e-05 | 129 | 30 | 3 | 85ee6e16959cb58a58f5b09edf1f78d9ce6a9441 | |
| ToppCell | Healthy_donor-B_cell|World / disease group, cell group and cell class (v2) | 1.38e-04 | 150 | 30 | 3 | a2dfed562de7f58f902b547acec5a13853c80c4c | |
| ToppCell | Control-PLT_4|World / Disease Group and Platelet Clusters | 1.49e-04 | 154 | 30 | 3 | a2a03c5e6759c45aeeedf1e68ecb5a0112ef9a20 | |
| ToppCell | E15.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 1.49e-04 | 154 | 30 | 3 | e65e4636646164610f33f7bbac0d879a3ea55986 | |
| ToppCell | ICU-SEP-Lymphocyte-T_NK-NK_CD56bright|ICU-SEP / Disease, Lineage and Cell Type | 1.61e-04 | 158 | 30 | 3 | 53a942cdab4a3c6813dbe11368135a24b8de1880 | |
| ToppCell | E18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.73e-04 | 162 | 30 | 3 | ec29c6f1c31e41ddcb041a49c593910edaf0532c | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.93e-04 | 168 | 30 | 3 | 9a8709d34865cfa668d8f3335dc34fc86fc32482 | |
| ToppCell | PND07-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_G2M|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.96e-04 | 169 | 30 | 3 | 563c267edaade0e5df192ad953801ef9768d4270 | |
| ToppCell | Severe-B_naive-11|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 2.03e-04 | 171 | 30 | 3 | 7c2699f19ca38414447a286f7658f507882d57c2 | |
| ToppCell | 3'-Child04-06-SmallIntestine-Endothelial-lymphatic_endothelial-LEC1_(ACKR4+)|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.10e-04 | 173 | 30 | 3 | 85083b9ce20351dd69aa2327ad087b848b4307ff | |
| ToppCell | droplet-Heart-nan-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.21e-04 | 176 | 30 | 3 | 749b47eac5436fa34e0d243ffbc6f1897f4e431e | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.29e-04 | 178 | 30 | 3 | 01dafd19de04eff459253eaa9a35debf8f3deedf | |
| ToppCell | Hippocampus-Neuronal-Inhibitory|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 2.44e-04 | 182 | 30 | 3 | b54ae650c04dfd0759c5f5e752b9bf684dd36516 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.48e-04 | 183 | 30 | 3 | 3c516fe5083f02bad1f464ed284010b4131a833c | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_plasma-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.48e-04 | 183 | 30 | 3 | dd15e1463a0d57d14800de0df0645c81c56926ae | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.48e-04 | 183 | 30 | 3 | 9c2689d76fc6d30f5ab093428aa669d0a98953cf | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_plasma|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.48e-04 | 183 | 30 | 3 | 8ace19c38b89556d2504258a63aa5a2b14f5cd36 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.52e-04 | 184 | 30 | 3 | 7294b379ce4cb8fa75e432559082f93cd106aaf5 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_plasma|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.64e-04 | 187 | 30 | 3 | 88d20f150df61ef0e3ee0c3e9895b094920c4b09 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_plasma-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.64e-04 | 187 | 30 | 3 | 158c2c003fd225ba61793fb06eece232fb063d05 | |
| ToppCell | LA-03._Atrial_Cardiomyocyte|World / Chamber and Cluster_Paper | 2.68e-04 | 188 | 30 | 3 | 6d249fe92d51a19da19ec14bb2262d394255d577 | |
| ToppCell | 3'_v3-blood-Lymphocytic_T_CD8-Trm/em_CD8|blood / Manually curated celltypes from each tissue | 2.68e-04 | 188 | 30 | 3 | 21730497f95dc271e4cdfaaf1da8b9ac6eec2ded | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c03-ITGA4|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.77e-04 | 190 | 30 | 3 | 91ba66d4b56c59523485b17738e93f14bb00afa4 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c09-GZMK-FOS_l|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.81e-04 | 191 | 30 | 3 | b9ef6d82b86271b7e0875a399bb9aae84ef5bad3 | |
| ToppCell | facs-Aorta-Heart-3m|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.85e-04 | 192 | 30 | 3 | 1ccc47792edf9ee23501c8e2165d11271636b66a | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-DN_to_DP_transition_(most_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.90e-04 | 193 | 30 | 3 | a6a864644e1b80b7417ea0a27281e79068a3fd3d | |
| ToppCell | NS-moderate-d_0-4|moderate / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.90e-04 | 193 | 30 | 3 | ea345d34440b25f65358a53dc72831998d1c3620 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.90e-04 | 193 | 30 | 3 | 523e2541f9f8d22b3c5263839a57cc1ab23d4963 | |
| ToppCell | COVID-19_Mild-PLT_4|World / Disease Group and Platelet Clusters | 2.90e-04 | 193 | 30 | 3 | 98a52523aa1efd5d14a2878ed106828a80a33aa2 | |
| ToppCell | normal_Lymph_Node-T/NK_cells-CD8_low_T|T/NK_cells / Location, Cell class and cell subclass | 2.90e-04 | 193 | 30 | 3 | 48809047d3194aff225fc43c3d5152c20434fe62 | |
| ToppCell | normal_Lymph_Node-T/NK_cells-CD8_low_T|normal_Lymph_Node / Location, Cell class and cell subclass | 2.90e-04 | 193 | 30 | 3 | e20ad6b62ad3aa386aa10b7a5d057d24a64ad386 | |
| ToppCell | COVID-19_Convalescent-PLT_4|COVID-19_Convalescent / Disease Group and Platelet Clusters | 2.94e-04 | 194 | 30 | 3 | ce1fad4e76a87f0c35e430ed1f2262395df882fd | |
| ToppCell | normal-na-Lymphocytic_NK-NK_bright|normal / PBMC cell types (v2) per disease, treatment status, and sex | 2.94e-04 | 194 | 30 | 3 | 8c5f716ce05c1f187de63c1b6948eb9f90ff34fe | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.94e-04 | 194 | 30 | 3 | b0a7f5ca0c6f4f5764a8b35b5de80d82b828c66c | |
| ToppCell | normal-na-Lymphocytic_NK-NK_bright-female|normal / PBMC cell types (v2) per disease, treatment status, and sex | 2.94e-04 | 194 | 30 | 3 | dc4aeee379423827e8d291cffe4dbdf2ff6d0bbe | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.99e-04 | 195 | 30 | 3 | 79114b3c78cc15c413bb58f0673e7215b784a9b6 | |
| ToppCell | 3'_v3-blood-Lymphocytic_NK-NK_CD56bright_CD16-|blood / Manually curated celltypes from each tissue | 2.99e-04 | 195 | 30 | 3 | 1470f562ebcfe7da367964ecfd6c7f43bcdb4a73 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.99e-04 | 195 | 30 | 3 | 5c86fddd6d0530beecf45ea5ba6b823123847696 | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_myocytic-stroma-muscle|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.99e-04 | 195 | 30 | 3 | 80b973d2a23ef9b101c90e1635e68c9a3f78f65d | |
| ToppCell | CV-Moderate-6|CV / Virus stimulation, Condition and Cluster | 3.03e-04 | 196 | 30 | 3 | 7bced0cc2112697593c478fa291b8ed3941fb811 | |
| ToppCell | ILEUM-non-inflamed-(6)_ILC-(6)_ILC1|(6)_ILC / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 3.03e-04 | 196 | 30 | 3 | 8a3a63129adfbe58558af91336f81d397c291ed0 | |
| ToppCell | ILEUM-inflamed-(6)_ILC-(6)_ILC1|(6)_ILC / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 3.03e-04 | 196 | 30 | 3 | c1d84d2e4ecc83134c3c694bed3cf035bd2742af | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.03e-04 | 196 | 30 | 3 | 17f17edadafdad9f24e88d708d7e1c765503131c | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-F|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.08e-04 | 197 | 30 | 3 | b597c292fc1cb381a4325fed15a32966c38def28 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.08e-04 | 197 | 30 | 3 | 35004d4728d33f15cc3be99a073b1ea965365c32 | |
| ToppCell | Control-PLT_4|Control / Disease Group and Platelet Clusters | 3.12e-04 | 198 | 30 | 3 | 387fd3037fd52e4d4c42de0588767e58af228b59 | |
| ToppCell | TCGA-Skin-Metastatic-Melanoma|TCGA-Skin / Sample_Type by Project: Shred V9 | 3.12e-04 | 198 | 30 | 3 | af4fb9eb2295c7b90624b38ba25619aa15254efa | |
| ToppCell | Severe-B_memory-3|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 3.12e-04 | 198 | 30 | 3 | a3050c126799e32f742a14396236572250476820 | |
| ToppCell | TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma|TCGA-Skin / Sample_Type by Project: Shred V9 | 3.12e-04 | 198 | 30 | 3 | 62cbf4b29e8af4983fb47a17f96da62682a5137e | |
| ToppCell | 10x_3'_v3-blood_(10x_3'_v3)-lymphocytic-T_lymphocytic-CD8-positive,_alpha-beta_cytokine_secreting_effector_T_cell|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.12e-04 | 198 | 30 | 3 | 34c564ece9a2b94dcf646e3c95b5be9c5ecfaafe | |
| ToppCell | TCGA-Skin-Metastatic|TCGA-Skin / Sample_Type by Project: Shred V9 | 3.12e-04 | 198 | 30 | 3 | ad39cce004867f083f8da1954e0cf5a263815184 | |
| ToppCell | COVID-19_Mild-PLT_4|COVID-19_Mild / Disease Group and Platelet Clusters | 3.12e-04 | 198 | 30 | 3 | 3d8c33dba759df0974aeb2b9a6b5167ae7a18e1f | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T9|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 3.17e-04 | 199 | 30 | 3 | e9c83555d2197b740797a9f33b64f8f7a7ba1ee2 | |
| ToppCell | COVID_vent-Lymphocytic-ILC|COVID_vent / Disease condition, Lineage, Cell class and subclass | 3.17e-04 | 199 | 30 | 3 | e3ff7fa1b1de1aaf6b46cdf49afa95bad457728a | |
| ToppCell | COVID_vent-Lymphocytic-ILC-NK_cell|COVID_vent / Disease condition, Lineage, Cell class and subclass | 3.17e-04 | 199 | 30 | 3 | 5f914962e2572b0c6372465b81b7496fa663d93c | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-F|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.17e-04 | 199 | 30 | 3 | b0a906586e58009f5ed9272fc29ba28e49c85ee6 | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-T/NK-dn_T|COVID-19_Mild / Disease, condition lineage and cell class | 3.17e-04 | 199 | 30 | 3 | f307d4887b28cf60a591439e278fd668409cb104 | |
| ToppCell | Control-Control-Lymphocyte-T/NK-dn_T|Control / Disease, condition lineage and cell class | 3.22e-04 | 200 | 30 | 3 | 10882c59b7aaf8bd4b5c00aa4ddbb9f7ac5b2cf5 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuronal-Intermediate|6m / Sample Type, Dataset, Time_group, and Cell type. | 3.22e-04 | 200 | 30 | 3 | 7c261e39ac30b318511373ab7302aa53b8b81b9c | |
| ToppCell | COVID-19|World / Disease, condition lineage and cell class | 3.22e-04 | 200 | 30 | 3 | 7dec470c379cd89f05a0f37c8628b21f136e52f0 | |
| ToppCell | COVID-19-COVID-19_Severe-Lymphocyte-T/NK-NK_CD56bright|COVID-19_Severe / Disease, condition lineage and cell class | 3.22e-04 | 200 | 30 | 3 | 12626d046a3ed8db1c9bd603ada5b97ead93e587 | |
| Drug | Nicardipine hydrochloride [54527-84-3]; Down 200; 7.8uM; MCF7; HT_HG-U133A | 5.51e-06 | 197 | 30 | 5 | 3215_DN | |
| Drug | Isocorydine (+) [475-67-2]; Down 200; 11.8uM; PC3; HT_HG-U133A | 5.93e-06 | 200 | 30 | 5 | 4505_DN | |
| Drug | Quercetine dihydrate [6151-25-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 8.82e-05 | 180 | 30 | 4 | 2859_DN | |
| Drug | Levonordefrin [829-74-3]; Up 200; 21.8uM; PC3; HT_HG-U133A | 1.02e-04 | 187 | 30 | 4 | 5854_UP | |
| Drug | Chlorambucil [305-03-3]; Down 200; 13.2uM; PC3; HT_HG-U133A | 1.06e-04 | 189 | 30 | 4 | 3788_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A | 1.13e-04 | 192 | 30 | 4 | 2523_UP | |
| Drug | Indomethacin [53-86-1]; Up 200; 11.2uM; HL60; HT_HG-U133A | 1.18e-04 | 194 | 30 | 4 | 2377_UP | |
| Drug | Pyrilamine maleate [59-33-6]; Up 200; 10uM; PC3; HT_HG-U133A | 1.18e-04 | 194 | 30 | 4 | 5869_UP | |
| Drug | Domperidone maleate; Down 200; 7.4uM; MCF7; HT_HG-U133A | 1.18e-04 | 194 | 30 | 4 | 2655_DN | |
| Drug | Chicago sky blue 6B [2610-05-1]; Up 200; 4uM; PC3; HT_HG-U133A | 1.20e-04 | 195 | 30 | 4 | 6626_UP | |
| Drug | Testosterone propionate [57-85-2]; Down 200; 11.6uM; MCF7; HT_HG-U133A | 1.20e-04 | 195 | 30 | 4 | 2649_DN | |
| Drug | oxaprozin; Down 200; 300uM; MCF7; HT_HG-U133A_EA | 1.20e-04 | 195 | 30 | 4 | 863_DN | |
| Drug | Estropipate [7280-37-7]; Down 200; 9.2uM; PC3; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 4472_DN | |
| Drug | Sulfaguanidine [57-67-0]; Down 200; 18.6uM; PC3; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 4257_DN | |
| Drug | Thioproperazine dimesylate [2347-80-0]; Up 200; 6.2uM; MCF7; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 2236_UP | |
| Drug | Sulfanilamide [63-74-1]; Down 200; 23.2uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 4474_DN | |
| Drug | Flavoxate hydrochloride [3717-88-2]; Up 200; 9.4uM; MCF7; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 7405_UP | |
| Drug | Fenbendazole [43210-67-9]; Up 200; 13.4uM; HL60; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 2360_UP | |
| Drug | SB 203580; Down 200; 1uM; MCF7; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 7061_DN | |
| Drug | Flavoxate hydrochloride [3717-88-2]; Down 200; 9.4uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 6326_DN | |
| Drug | Clorsulon [60200-06-8]; Up 200; 10.6uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 7264_UP | |
| Drug | Harmalol hydrochloride dihydrate [6028-07-5]; Up 200; 14.6uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 5076_UP | |
| Drug | Cefepime hydrochloride [123171-59-5]; Up 200; 7.4uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 5761_UP | |
| Drug | Tiaprofenic acid [33005-95-7]; Down 200; 15.4uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 4091_DN | |
| Drug | Phentolamine hydrochloride [73-05-2]; Up 200; 12.6uM; HL60; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 2362_UP | |
| Drug | Oxyphenbutazone [129-20-4]; Down 200; 12.4uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 4506_DN | |
| Drug | Gentamicine sulfate [1405-41-0]; Up 200; 2.6uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 5883_UP | |
| Drug | Carbimazole [22232-54-8]; Up 200; 21.4uM; HL60; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 2437_UP | |
| Drug | Phensuximide [86-34-0]; Down 200; 21.2uM; HL60; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 2960_DN | |
| Drug | haloperidol; Down 200; 10uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 4468_DN | |
| Drug | Oxaprozin [21256-18-8]; Up 200; 13.6uM; MCF7; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 4352_UP | |
| Drug | Tocopherol (R,S) [10191-41-0]; Up 200; 9.2uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 6616_UP | |
| Drug | Etidronic acid, disodium salt [7414-83-7]; Up 200; 16uM; MCF7; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 3325_UP | |
| Drug | AG-012559 [369370-06-9]; Down 200; 10uM; MCF7; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 6889_DN | |
| Drug | Aspartic acid, N-acetyl (R,S) [997-55-7]; Down 200; 22.8uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 4007_DN | |
| Drug | Dinoprost trometamol [38362-01-5]; Down 200; 8.4uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 6308_DN | |
| Drug | Rifampicin [13292-46-1]; Up 200; 4.8uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 4008_UP | |
| Drug | SR-95639A [115767-94-7]; Down 200; 10uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 6632_DN | |
| Drug | Homosalate [118-56-9]; Up 200; 15.2uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 4533_UP | |
| Drug | 5149715; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 1.30e-04 | 199 | 30 | 4 | 890_UP | |
| Drug | Levodopa [59-92-7]; Up 200; 20.2uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 4571_UP | |
| Drug | Nomifensine maleate [32795-47-4]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 1.32e-04 | 200 | 30 | 4 | 2224_UP | |
| Disease | intellectual developmental disorder with ocular anomalies and distinctive facial features (implicated_via_orthology) | 9.99e-07 | 2 | 30 | 2 | DOID:0081301 (implicated_via_orthology) | |
| Disease | Dickkopf-related protein 4 measurement | 2.79e-05 | 8 | 30 | 2 | EFO_0008110 | |
| Disease | creatine kinase measurement | 2.97e-05 | 59 | 30 | 3 | EFO_0004534 | |
| Disease | attention deficit hyperactivity disorder (implicated_via_orthology) | 3.72e-04 | 28 | 30 | 2 | DOID:1094 (implicated_via_orthology) | |
| Disease | gait measurement | 4.73e-04 | 150 | 30 | 3 | EFO_0007680 | |
| Disease | cryptic phenotype measurement | 1.05e-03 | 47 | 30 | 2 | EFO_0021487 | |
| Disease | metabolic syndrome | 1.09e-03 | 200 | 30 | 3 | EFO_0000195 | |
| Disease | health literacy measurement | 1.33e-03 | 53 | 30 | 2 | EFO_0010104 | |
| Disease | asthma, endometriosis | 2.58e-03 | 74 | 30 | 2 | EFO_0001065, MONDO_0004979 | |
| Disease | interleukin 10 measurement | 2.86e-03 | 78 | 30 | 2 | EFO_0004750 | |
| Disease | breast carcinoma | 3.38e-03 | 1019 | 30 | 5 | EFO_0000305 | |
| Disease | influenza A (H1N1) | 3.54e-03 | 87 | 30 | 2 | EFO_1001488 | |
| Disease | physical activity | 3.62e-03 | 88 | 30 | 2 | EFO_0003940 | |
| Disease | lipid measurement, intermediate density lipoprotein measurement | 4.29e-03 | 96 | 30 | 2 | EFO_0004529, EFO_0008595 | |
| Disease | phospholipid measurement, intermediate density lipoprotein measurement | 4.56e-03 | 99 | 30 | 2 | EFO_0004639, EFO_0008595 | |
| Disease | Adenoid Cystic Carcinoma | 4.65e-03 | 100 | 30 | 2 | C0010606 | |
| Disease | sodium measurement | 4.93e-03 | 103 | 30 | 2 | EFO_0009282 | |
| Disease | immature platelet count | 5.21e-03 | 106 | 30 | 2 | EFO_0803544 | |
| Disease | gallstones | 5.40e-03 | 108 | 30 | 2 | EFO_0004210 | |
| Disease | atrial fibrillation | 6.22e-03 | 371 | 30 | 3 | EFO_0000275 | |
| Disease | glycoprotein measurement | 6.52e-03 | 119 | 30 | 2 | EFO_0004555 | |
| Disease | immature platelet measurement | 6.52e-03 | 119 | 30 | 2 | EFO_0803541 | |
| Disease | platelet component distribution width | 6.87e-03 | 755 | 30 | 4 | EFO_0007984 | |
| Disease | C-reactive protein measurement | 6.88e-03 | 1206 | 30 | 5 | EFO_0004458 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| ESLDKHKHKKLQSFY | 186 | O42043 | |
| ESLDKHKHKKLQSFY | 296 | Q9UKH3 | |
| HLMKEFLDKKKYHND | 51 | O43683 | |
| FKNKCDIEKHKSYHI | 621 | Q86V15 | |
| DAAKLKYKKANEEHH | 171 | A7E2U8 | |
| EKSHLKHIYEKKAHD | 541 | Q8N8E3 | |
| HKTKKNDDPSKDYHV | 81 | Q8WZ64 | |
| HYDSIAEKQKDLDKK | 76 | Q63HQ0 | |
| DHYLQEAKKLKHNAD | 916 | Q9UHB7 | |
| KKLHNDLYFIKKAHS | 506 | Q9UFE4 | |
| YLKDVKQHHVKADKR | 486 | Q969V3 | |
| KAIKHLFKDHAYALA | 361 | Q9NWU1 | |
| HLKKHKAALAAAQYK | 1481 | Q15652 | |
| KAANQLDKDHAKEYK | 116 | Q765P7 | |
| KKVANQLDKDHAKEY | 116 | O43312 | |
| QLDKDHAKEYKKARQ | 121 | O43312 | |
| NNEEHEYASKKRKKD | 56 | Q8TCJ0 | |
| KELEAAKKAYHLACK | 151 | Q9BY11 | |
| AKKAYHLACKEEKLA | 156 | Q9BY11 | |
| ESLDKHKHKKLQSFY | 186 | P61566 | |
| ESLDKHKHKKLQSFY | 186 | P61567 | |
| YKLKKEHNEFHANKA | 246 | P57773 | |
| ESLDKHKHKKLQSFY | 296 | P61565 | |
| ESLDKHKHKKLQSFY | 186 | Q9HDB8 | |
| KDAHPKLHVYKKEAF | 301 | Q6UWV6 | |
| HYESLQTAKKKDEAK | 156 | O00499 | |
| LTHYDAKKKAAHAAK | 361 | P48426 | |
| KKHKSEEHNDKEHSS | 81 | Q7L4I2 | |
| SHSQDKHHEKEKKKY | 221 | P55197 | |
| KSWRDEKKENYHKHA | 491 | Q9UKI8 | |
| DELYKVTKEHTHNKK | 146 | Q5GJ75 | |
| KDHHDLAKKNYKHWR | 281 | Q9BVS5 | |
| YKEHLEGQKHKKKEA | 346 | Q96KR1 | |
| LAEHQKTHEKEKSYA | 456 | Q8TBC5 | |
| KYEKLEKHSANHNVK | 1201 | Q9BXT5 | |
| FRLNDSHKHKDKHKD | 16 | P11387 | |
| HAIKYEAHSDKAKES | 41 | Q9UN37 | |
| YKEKFDNEMKDKKHH | 231 | O76041 | |
| LNYKAKHEGEKFKCH | 771 | P20929 | |
| LVSENKYKDHVKKHL | 5646 | P20929 |